Positive stool samples by pathogen and study sites. by Amete Mihret Teshale (12072758)

Subjects:

Odds Ratio of multivariable analysis of factors for <i>Campylobacter species.</i> by Amete Mihret Teshale (12072758)

Subjects:

Odds ratio of multivariable analysis of factors for non-typhoidal <i>Salmonella.</i> by Amete Mihret Teshale (12072758)

Subjects:

Socio-demographic and clinical characteristics of participants by study site. by Amete Mihret Teshale (12072758)

Subjects:

(a) Seasonal trends of non-typhoidal <i>Salmonella</i> by study sites. (b) Seasonal trends of <i>Campylobacter species</i> by study sites. (c) Seasonal trends of Shiga toxin-produc... by Amete Mihret Teshale (12072758)

Subjects:

Mean age of patients submitting stool samples per study site. by Amete Mihret Teshale (12072758)

Subjects:

Study areas of sample collection in Ethiopia, eastern Africa by Amete Mihret Teshale (12072758)

Subjects:

Prevaelnce of different pathogens by location. by Amete Mihret Teshale (12072758)

Subjects:

Odds ratio of multivariable analysis of factors for Shiga-toxin producing <i>Escherichia coli</i> (<i>stx</i> by Amete Mihret Teshale (12072758)

Subjects:

Mean concentrations of sum sesquiterpenes and single sesquiterpenes: β-caryophyllene, α-humulene, δ-selinene, γ-cadinene, δ-cadinene, nerolidol, maaliol, germacrene D-4-ol, spathul... by Valtcho D. Zheljazkov (627617)

Genera associated with FC, symptom score or week to treatment. by Katrine Carlsen (5477300)

Behaviour and significance of reservoir evaporation and seepage losses – an experience of four reservoirs in Damodar River Valley, India by Dipankar Chaudhuri (498103)

“…During non-monsoon months, seepage and evaporation losses were significant, which indicated necessity of consideration of losses in water balance equation for estimation of inflow.…”

The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. by Jiefeng Zhao (9090305)

Immunogenicity results of different vaccination schemes at different time points. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against acute-care hospitalization attributed to laboratory-confirmed infections during the differen... by Rima Moghnieh (679199)

Subjects:

Immunogenicity assessment groups based on the primary and booster vaccination schemes and timeframe from the second or booster dose. by Rima Moghnieh (679199)

Subjects:

Humoral immune responses to SARS-CoV-2 spike protein following various primary vaccination schemes and booster doses with Sinopharm or Pfizer vaccines among COVID-19-naïve particip... by Rima Moghnieh (679199)

Subjects:

Fig 4 - by Rima Moghnieh (679199)

Subjects:

COVID-19 in Lebanon: The daily number of COVID-19 cases throughout the waves of the pandemic in Lebanon and associated SARS-CoV-2 variants between January 2021 and September 2022. by Rima Moghnieh (679199)

Subjects: